Geneos Wealth Management’s Recursion Pharmaceuticals RXRX Stock Holding History

Geneos Wealth Management’s Portfolio RXRX Stock Details RXRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-350	Closed	-$1.71K	–	2543
2025 Q3	$1.71K	Sell	350 -89	-20%	-$467	﹤0.01%	2340
2025 Q2	$2.22K	Sell	439 -439	-50%	-$2.16K	﹤0.01%	2788
2025 Q1	$4.64K	Buy	878 +328	+60%	+$2.39K	﹤0.01%	2767
2024 Q4	$3.72K	Buy	550 +200	+57%	+$1.34K	﹤0.01%	2436
2024 Q3	$2.31K	Hold	350	–	–	﹤0.01%	2265
2024 Q2	$2.63K	Hold	350	–	–	﹤0.01%	1839
2024 Q1	$3.49K	Buy	+350	New	+$3.9K	﹤0.01%	1785

Other funds holding RXRX

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

SoftBank Group Tokyo, Japan $11.4B AUM 27.91% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

MCMU

MIC Capital Management (UK) London, United Kingdom $352M AUM 0.23% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

Geneos Wealth Management's RXRX Position: Q4 2025 in Review

Geneos Wealth Management sold out of Recursion Pharmaceuticals (RXRX) in Q4 2025, closing a stake of 350 shares — an estimated $1.71K sold.

Geneos Wealth Management first reported a position in RXRX in Q1 2024 and held it in 7 quarters. The position peaked at $4.64K in Q1 2025. 333 funds tracked by Wall St. Rank hold RXRX as of Q4 2025.

Geneos Wealth Management reported no remaining Recursion Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
Geneos Wealth Management sold 350 Recursion Pharmaceuticals shares in Q4 2025, an estimated $1.71K.
Geneos Wealth Management first reported a position in Recursion Pharmaceuticals in Q1 2024 and held it in 7 quarters.
Geneos Wealth Management's Recursion Pharmaceuticals position peaked at $4.64K in Q1 2025.
333 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q4 2025.

Based on Geneos Wealth Management's 13F filing for Q4 2025, filed 28 Jan 2026.